new weight loss drug australia
Posted: Wed Jan 01, 2025 2:28 pm
A new weight loss drug called Mounjaro (tirzepatide) has recently been approved by the Therapeutic Goods Administration (TGA) in Australia for treating obesity. Mounjaro was initially approved for treating type 2 diabetes, but its effectiveness in weight management has led to its expanded use.
Key Points about Mounjaro
Indications: Approved for chronic weight management in adults with a BMI of 30 kg/m² or higher, or 27 kg/m² with at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, cardiovascular disease).
Mechanism: Mounjaro works by mimicking the action of the body's own GLP-1 hormone, helping to regulate blood sugar levels and manage appetite.
Effectiveness: Clinical trials have shown that obese patients can lose up to 20% of their body weight when taking the highest doses of the drug.
Side Effects: Common side effects include diarrhea, nausea, and vomiting. Rare but serious side effects may include acute pancreatitis and gallbladder disease
Key Points about Mounjaro
Indications: Approved for chronic weight management in adults with a BMI of 30 kg/m² or higher, or 27 kg/m² with at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, cardiovascular disease).
Mechanism: Mounjaro works by mimicking the action of the body's own GLP-1 hormone, helping to regulate blood sugar levels and manage appetite.
Effectiveness: Clinical trials have shown that obese patients can lose up to 20% of their body weight when taking the highest doses of the drug.
Side Effects: Common side effects include diarrhea, nausea, and vomiting. Rare but serious side effects may include acute pancreatitis and gallbladder disease